Megaphen

# Megaphen ## Overview - **Classification**: Novel Broad-Spectrum Antibiotic (Oxazolidinone Derivative) - **Mechanism**: Inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S ribosomal subunit, preventing initiation complex formation. ## Primary Indications 1. **Complicated Skin and Soft Tissue Infections (cSSTI)** - Infections requiring systemic antibiotic treatment. 2. **Community-Acquired Bacterial Pneumonia (CABP)** - Pneumonia acquired outside of hospitals. 3. **Vancomycin-Resistant Enterococcus (VRE) Infections** - Including bacteremia. ## Adult Dosing ### Standard Dosing **Complicated Skin and Soft Tissue Infections (cSSTI) / Community-Acquired Bacterial Pneumonia (CABP)** - **Dose**: **400 mg** - **Frequency**: **q12h** - **Route**: Intravenous (IV) or Oral (PO) - **Duration**: **7-14 days** for cSSTI; **5-10 days** for CABP. **Vancomycin-Resistant Enterococcus (VRE) Infections** - **Dose**: **600 mg** - **Frequency**: **q12h** - **Route**: Intravenous (IV) or Oral (PO) - **Duration**: **10-28 days**. - **Maximum Dose**: **600 mg** per dose, **1200 mg** per day. ### Dose Adjustments - **Renal Impairment**: No dose adjustment needed for CrCl >15 mL/min. For CrCl <15 mL/min (including hemodialysis/PD), administer dose after dialysis; monitor for increased adverse effects. - **Hepatic Impairment**: Mild-moderate (Child-Pugh A/B): No adjustment. Severe (Child-Pugh C): Use with caution; monitor for increased drug levels. - **Elderly Patients**: No specific dose adjustment needed based on age; monitor renal function. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not routinely recommended due to limited data and safety concerns. If life-threatening infection with no alternatives: **10 mg/kg** IV. - **Frequency**: **q12h** (off-label). - **Maximum**: **10 mg/kg/dose**. - **Special Notes**: Use only when benefits outweigh risks. Monitor CBC, LFTs, and lactate closely. ### Infants (1-12 months) - **Dose**: **10 mg/kg** IV/PO. - **Frequency**: **q8h**. - **Maximum**: **10 mg/kg/dose** or **400 mg/dose**, whichever is less. ### Children (1-12 years) - **Dose**: **10 mg/kg** IV/PO. - **Frequency**: **q8h**. - **Maximum**: **600 mg/dose** (do not exceed adult maximum dose). ### Adolescents (13-18 years) - **Dose**: Adult dosing typically applies: **400-600 mg** IV/PO. - **Frequency**: **q12h**. - **Maximum**: **600 mg/dose** (adult maximum dose). ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Megaphen or any component. - **Absolute**: Concurrent use with Monoamine Oxidase Inhibitors (MAOIs) or within 2 weeks of MAOI use (e.g., phenelzine, selegiline, linezolid). - **Relative**: Uncontrolled hypertension, pheochromocytoma, carcinoid syndrome (due to weak MAOI activity). ### Common Adverse Effects - **Very Common (>10%)**: Nausea, diarrhea, headache, insomnia. - **Common (1-10%)**: Vomiting, dizziness, rash, myelosuppression (e.g., thrombocytopenia, anemia), peripheral neuropathy. - **Serious but Rare**: Serotonin syndrome, lactic acidosis, optic neuropathy, C. difficile infection, severe myelosuppression. ### Key Drug Interactions - **MAOIs (e.g., phenelzine, isocarboxazid)**: Severe serotonin syndrome, hypertensive crisis. **ABSOLUTELY contraindicated**. - **SSRIs/SNRIs (e.g., sertraline, venlafaxine)**: Increased risk of serotonin syndrome. Monitor closely; consider alternatives if possible. - **Tyramine-rich foods / Vasopressors (e.g., pseudoephedrine, epinephrine)**: Risk of hypertensive crisis due to weak MAOI activity. Limit tyramine intake; use vasopressors cautiously. - **Myelosuppressants (e.g., methotrexate, azathioprine)**: Increased risk of myelosuppression. Monitor CBC more frequently. ## Monitoring & Follow-up - **Before Treatment**: Complete Blood Count (CBC) with platelets, Liver Function Tests (LFTs), renal function. - **During Treatment**: CBC with platelets **weekly**, especially if treatment >2 weeks. Vision assessment if treatment >28 days. - **Clinical Signs**: Monitor for vision changes, numbness/tingling, severe headache, confusion, unexplained nausea/vomiting, fever, signs of bleeding. ## Clinical Pearls - 💡 Oral bioavailability is ~100%, allowing for a convenient IV to PO switch. Administer with or without food. - 💡 Counsel patients on symptoms of serotonin syndrome (agitation, confusion, tachycardia) and myelosuppression (unusual bruising/bleeding, fatigue). - 💡 Advise patients to avoid large amounts of tyramine-rich foods (e.g., aged cheese, cured meats, red wine, fava beans). - 💡 Discontinue Megaphen if optic neuropathy or severe myelosuppression occurs. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.